Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cutia TherapeuticsHKSE:02487 +6.10%40 PB Ratio is 0.97 as of Jul. 21, 2026, which is 44% below its 10-year median of 1.73. GuruFocus rates HKSE:02487 with a GF Score™ of 40/100 and a GF Value™ of HK$16.27 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,229 Biotechnology companies, Cutia Therapeutics ranks better than 82.75% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cutia Therapeutics PB Ratio Related Terms
Cutia Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Cutia Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02487 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Cutia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cutia Therapeutics (HKSE:02487) has a PB Ratio of 0.97 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cutia Therapeutics and its competitors. This is 44% below median its historical median of 1.73. Over the past decade, Cutia Therapeutics' PB Ratio has ranged from 0.90 to 3.75. According to the industry distribution chart, Cutia Therapeutics ranks #212 out of 1229 companies in the Biotechnology industry, placing it in the top 17.2%.
Is Cutia Therapeutics' PB Ratio too high?
Cutia Therapeutics' current PB Ratio of 0.97 is 44% below median its 10-year median of 1.73. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 3.75. The Biotechnology industry median PB Ratio is 2.79. Cutia Therapeutics' value of 0.97 is 65.2% below this industry median. Based on the distribution chart, Cutia Therapeutics ranks #212 out of 1229 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cutia Therapeutics ranks #212 out of 1229 companies for PB Ratio. This places Cutia Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.79. Cutia Therapeutics' value of 0.97 is 65.2% below this benchmark. Historically, Cutia Therapeutics' own PB Ratio has ranged from 0.90 to 3.75 over the past decade. While the company's 10-year median is 1.73 vs. the industry median of 2.79, Cutia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cutia Therapeutics's current PB Ratio of 0.97 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cutia Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cutia Therapeutics's current PB Ratio is 0.97, which is 44% below median its own 10-year median of 1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.27, compared to a current price of HK$2.61 — trading 84% below its estimated fair value. The current PB Ratio is 0.97, which is 44% below median its 10-year median of 1.73 and 65.2% below the Biotechnology industry median of 2.79. Cutia Therapeutics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current PB Ratio is 0.97 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$2.61 is trading 84% below its estimated GF Value™ of HK$16.27.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
PB Ratio: 0.97 (44% below median its 10-year median of 1.73)
GF Value™: HK$16.27 vs. price of HK$2.61 (84% below fair value)
Industry Position: 65.2% below the Biotechnology median (#212 of 1229)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score
Get the complete analysis for HKSE:02487
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
